CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 107 enrolled
Drug / intervention
Carfilzomib +2 moredrug
Likely dose
Dexamethasone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02335983
NCT02335983Phase 1Completed
CompareCT.gov

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Amgen·interventional·Posted Jan 12, 2015·Updated Nov 6, 2020

In Brief

A Phase 1 clinical trial evaluating Carfilzomib, Lenalidomide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 107 participants across 59 sites.

Detailed Summary

The purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 12, 2015
Enrollment StartApr 30, 2015
Primary CompletionOct 28, 2019
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 11.5 years ago

Interventions

Carfilzomibdrug

Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.

Lenalidomidedrug

Administered orally once daily on days 1-21 of each 28-day cycle.

Dexamethasonedrug

Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.